Using ibrutinib in earlier lines of treatment results in better outcomes for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma

Affiliations

• ¹ Division of Hematology, Department of Internal Medicine, The Ohio State University Medical Center, Columbus, OH, USA.
• ² Department of Hematology, Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy.
• ³ Department of Haematology, St. James's University Hospital, Leeds, UK.
• ⁴ Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, USA.
• ⁵ Department of Haematology, The Leeds Teaching Hospitals, St. James Institute of Oncology, Leeds, UK.
• ⁶ Division of Experimental Oncology, Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milano, Italy.
• ⁷ Department of Haematology, Royal North Shore Hospital, University of Sydney, Sydney, Australia.
• ⁸ Department of Biostatistics, Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA.
• ⁹ Department of Medical Affairs, Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA.
• ¹⁰ Department of Clinical Science, Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA.
• ¹¹ Department of Hematology and Oncology, UC Irvine, Chao Family Comprehensive Cancer Center, Irvine, CA, USA.
• ¹² Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA.